arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

LEXICON PHARMACEUTICALS, INC.

LXRX
$2.06 ▼ -0.11 (-5.07%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
68 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
27
Health
Poor
Bearish
auto_awesome

Analytical Summary

LEXICON PHARMACEUTICALS, INC. faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $901.6M
Dividend Yield —
Revenue Growth -97.6% ↘
Op. Margin None
ROIC -9.3% ↘
FCF / Share $-0.02 ↗
Trailing P/E —
Price / Book 5.3x
FCF Yield —
Debt / Equity 0.29
info Valuation on last close. End-of-day price, Sep 23, 2026.

68-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$692.00K
↓ -97.6% —
Net Income Profit after all expenses
$-1.04M
↑ +95.9% —
Operating Margin Operating profit as % of sales
-4.7%
↑ +98.2% 2th
FCF / Share Free cash flow per share
$-0.02
↑ +42.9% —
Long-Term Debt Long-term obligations
$51.44M
↑ +3.5% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability ↑
2
Returns ↑
17
Financial Health ↑
44
Cash Quality ↑
77

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 18 years · 68 quarters